-
European Review For Medical and... May 2017To investigate the effects of Artesunate (ART) on the Raji cell proliferation, apoptosis and autophagy with Raji cells of Burkitt's lymphoma as the objects of study, and...
OBJECTIVE
To investigate the effects of Artesunate (ART) on the Raji cell proliferation, apoptosis and autophagy with Raji cells of Burkitt's lymphoma as the objects of study, and to investigate the anti-tumor mechanism of ART.
MATERIALS AND METHODS
Morphological examinations of apoptotic and autophagy were performed. MTT assay was used to detect the cell proliferation after ART treatment. The changes in cell apoptosis and cell cycle were detected by flow cytometer. The expression of Beclin-1 mRNA was detected by qRT-PCR. The expressions of Beclin-1, LC3-I/II and Caspase-3 were detected by Western blotting.
RESULTS
After Raji cells had been treated with ART, typical morphological changes of cell apoptosis were observed, and the proliferation activity of Raji cells was significantly inhibited in a time- and concentration-dependent manner. Compared with that in control group, the apoptotic rate in the treatment group was significantly increased and the expression of the apoptosis-related protein was significantly different. ART induced Raji cells to produce autophagosome, and the expressions of relevant autophagy proteins were significantly different, inducing the autophagy.
CONCLUSIONS
ART can significantly inhibit the proliferation of Raji cells of Burkitt's lymphoma and induce the apoptosis and autophagy excitation of Raji cells with the co-existence of autophagy and apoptosis.
Topics: Apoptosis; Artemisinins; Artesunate; Autophagy; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Humans
PubMed: 28537658
DOI: No ID Found -
The Journal of Infectious Diseases Jun 2020Endemic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections. However, the role of Kaposi sarcoma-associated... (Comparative Study)
Comparative Study
BACKGROUND
Endemic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections. However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endemic in Africa, has not been evaluated as a cofactor in eBL pathogenesis.
METHODS
Multiplexed seroprofiles for EBV, malaria, and KSHV were generated for 266 eBL patients, 78 non-eBL cancers, and 202 healthy children. KSHV and EBV loads were quantified by PCR.
RESULTS
KSHV seroprevalence did not differ by study group but was associated with age. Seropositivity, defined by K8.1/LANA or in combination with 5 other KSHV antigens (ORF59, ORF65, ORF61, ORF38, and K5) was associated with antimalarial antibody levels to AMA1 (odds ratio [OR], 2.41, P < .001; OR, 2.07, P < .001) and MSP1 (OR, 2.41, P = .0006; OR, 5.78, P < .001), respectively. KSHV loads did not correlate with antibody levels nor differ across groups but were significantly lower in children with detectable EBV viremia (P = .014).
CONCLUSIONS
Although KSHV-EBV dual infection does not increase eBL risk, EBV appears to suppress reactivation of KSHV while malaria exposure is associated with KSHV infection and/or reactivation. Both EBV and malaria should, therefore, be considered as potential effect modifiers for KSHV-associated cancers in sub-Saharan Africa.
Topics: Adolescent; Age Factors; Burkitt Lymphoma; Child; Child, Preschool; Coinfection; Female; Herpesviridae; Herpesviridae Infections; Humans; Infant; Kenya; Male; Sarcoma, Kaposi; Seroepidemiologic Studies
PubMed: 32072172
DOI: 10.1093/infdis/jiaa060 -
Journal of Medical Case Reports Mar 2017Burkitt lymphoma is a high-grade B cell lymphoma which accounts for less than 1% of all adult cases of non-Hodgkin lymphoma. Rare instances of Burkitt lymphoma... (Review)
Review
BACKGROUND
Burkitt lymphoma is a high-grade B cell lymphoma which accounts for less than 1% of all adult cases of non-Hodgkin lymphoma. Rare instances of Burkitt lymphoma developing secondary to prior irradiation have been described in the literature.
CASE PRESENTATION
We report a case of a 90-year-old white woman with a recent history of irradiation for Hodgkin lymphoma, who presented with primary Burkitt lymphoma of the supraglottic larynx. She underwent emergency awake tracheostomy with biopsy. A histopathological examination confirmed non-Hodgkin, B cell lymphoma of Burkitt type. Given her age and poor functional status, she underwent treatment with palliative radiotherapy.
CONCLUSIONS
A literature review was performed to clarify the clinical characteristics of radiation-induced Burkitt lymphoma in the head and neck, as well as its diagnosis and management. The present case represents the second case of radiation-induced Burkitt lymphoma in the head and neck in the reported literature, and the first in the supraglottic larynx. It highlights the need to maintain a broad differential in the assessment of malignancies of the larynx, particularly in patients with a prior history of radiation treatment.
Topics: Aged, 80 and over; Burkitt Lymphoma; Fatal Outcome; Female; Hodgkin Disease; Humans; Laryngeal Neoplasms; Larynx; Neoplasms, Radiation-Induced; Tomography, X-Ray Computed
PubMed: 28279203
DOI: 10.1186/s13256-017-1209-3 -
The Pan African Medical Journal 2020Primary lymphomas of the colon account for 0.5% of all primary colon malignancies. Burkitt´s lymphoma is a B-cell lymphoma with aggressive clinical behavior. Herein, we...
Primary lymphomas of the colon account for 0.5% of all primary colon malignancies. Burkitt´s lymphoma is a B-cell lymphoma with aggressive clinical behavior. Herein, we describe a case of a male patient who presented with signs of large bowel obstruction, underwent surgery and found to suffer from Burkitt´s lymphoma of the ileocecal region. The histopathological examination was indicative for Burkitt´s lymphoma. To the best of our insight this is one of the few reported cases of such type of lymphoma in an adult patient presenting with bowel obstruction. Burkitt´s lymphoma is a rare malignancy in adults affecting gastrointestinal tract. It has a high proliferation potential and can rapidly progress to advanced disease. Early diagnosis is necessary to prevent complications and improve overall prognosis.
Topics: Burkitt Lymphoma; Colonic Neoplasms; Humans; Intestinal Obstruction; Male; Middle Aged; Prognosis
PubMed: 33708314
DOI: 10.11604/pamj.2020.36.223.24718 -
Cellular and Molecular Life Sciences :... Sep 2022The link between cancer and aberrant glycosylation has recently become evident. Glycans and their altered forms, known as tumour-associated carbohydrate antigens...
The link between cancer and aberrant glycosylation has recently become evident. Glycans and their altered forms, known as tumour-associated carbohydrate antigens (TACAs), are diverse, complex and difficult to target therapeutically. Lectins are naturally occurring glycan-binding proteins that offer a unique opportunity to recognise TACAs. T cells expressing chimeric antigen receptors (CARs) have proven to be a successful immunotherapy against leukaemias, but so far have shown limited success in solid tumours. We developed a panel of lectin-CARs that recognise the glycosphingolipid globotriaosylceramide (Gb3), which is overexpressed in various cancers, such as Burkitt's lymphoma, colorectal, breast and pancreatic. We have selected the following lectins: Shiga toxin's B-subunit from Shigella dysenteriae, LecA from Pseudomonas aeruginosa, and the engineered lectin Mitsuba from Mytilus galloprovincialis as antigen-binding domains and fused them to a well-known second-generation CAR. The Gb3-binding lectin-CARs have demonstrated target-specific cytotoxicity against Burkitt's lymphoma-derived cell lines as well as solid tumour cells from colorectal and triple-negative breast cancer. Our findings reveal the big potential of lectin-based CARs as therapeutical applications to target Gb3 and other TACAs expressed in haematological malignancies and solid tumours.
Topics: Burkitt Lymphoma; Colorectal Neoplasms; Humans; Lectins; Polysaccharides; Receptors, Chimeric Antigen; T-Lymphocytes
PubMed: 36097202
DOI: 10.1007/s00018-022-04524-7 -
Molecules (Basel, Switzerland) Dec 2023Chronic lymphocytic leukaemia (CLL) is a malignancy of the immune B lymphocyte cells and is the most common leukaemia diagnosed in developed countries. In this paper, we...
Chronic lymphocytic leukaemia (CLL) is a malignancy of the immune B lymphocyte cells and is the most common leukaemia diagnosed in developed countries. In this paper, we report the synthesis and antiproliferative effects of a series of ()-9-(2-nitrovinyl)anthracenes and related nitrostyrene compounds in CLL cell lines and also in Burkitt's lymphoma (BL) cell lines, a rare form of non-Hodgkin's immune B-cell lymphoma. The nitrostyrene scaffold was identified as a lead structure for the development of effective compounds targeting BL and CLL. The series of structurally diverse nitrostyrenes was synthesised via Henry-Knoevenagel condensation reactions. Single-crystal X-ray analysis confirmed the structure of ()-9-chloro-10-(2-nitrobut-1-en-1-yl)anthracene () and the related 4-(anthracen-9-yl)-1-1,2,3-triazole (). The ()-9-(2-nitrovinyl)anthracenes and were found to elicit potent antiproliferative effects in both BL cell lines EBVMUTU-1 (chemosensitive) and EBV DG-75 (chemoresistant) with >90% inhibition at 10 μM. Selected ()-9-(2-nitrovinyl)anthracenes demonstrated potent antiproliferative activity in CLL cell lines, with IC values of 0.17 μM (HG-3) and 1.3 μM (PGA-1) for compound . The pro-apoptotic effects of the most potent compounds , , , and were demonstrated in both CLL cell lines HG-3 and PGA-1. The ()-nitrostyrene and ()-9-(2-nitrovinyl)anthracene series of compounds offer potential for further development as novel chemotherapeutics for CLL.
Topics: Humans; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytes; Cell Line; Anthracenes
PubMed: 38138584
DOI: 10.3390/molecules28248095 -
World Journal of Gastroenterology Feb 2022Malignant lymphoma is a rare form of gallbladder malignancy. Most of these malignancies are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type...
BACKGROUND
Malignant lymphoma is a rare form of gallbladder malignancy. Most of these malignancies are diffuse large B-cell lymphomas or mucosa-associated lymphoid tissue-type lymphomas; however, Burkitt's lymphoma of the gallbladder is extremely rare, and only two previous reports are available in the literature. Herein, we report a rare case of Burkitt's lymphoma of the gallbladder mimicking gallbladder adenocarcinoma.
CASE SUMMARY
An 83-year-old man with no abdominal complaints was found to have a gallbladder tumor and periportal lymph node enlargement on computed tomography (CT) performed for hypertension screening. His laboratory data revealed slightly elevated serum levels of carcinoembryonic antigen and soluble interleukin 2 receptor. Imaging examinations revealed two irregular and contrast-enhanced masses extending into the gallbladder lumen, but these did not infiltrate the serosa. Moreover, a periportal lymph node had enlarged to 30 mm. Based on these findings, we diagnosed the patient as having gallbladder adenocarcinoma with lymph node metastasis, which was treated using bile duct resection with gallbladder bed resection and periportal lymph node dissection. However, the patient was finally diagnosed as having Burkitt's lymphoma. Although the surgical margin was pathologically negative, recurrence was noted at the hepatic radical margin and superior pancreaticoduodenal lymph nodes on positron emission tomography/CT soon after discharge. Thus, he was referred to a hematologist and started receiving treatment with reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone.
CONCLUSION
Burkitt's lymphoma can occur in the gallbladder. Biopsy can be useful in cases with findings suggestive of gallbladder malignant lymphoma.
Topics: Aged, 80 and over; Burkitt Lymphoma; Cholecystectomy; Gallbladder Neoplasms; Humans; Lymphatic Metastasis; Male
PubMed: 35317428
DOI: 10.3748/wjg.v28.i6.675 -
World Journal of Surgical Oncology Jul 2023Primary hepatic Burkitt lymphoma (PHBL) in children is an extremely rare hepatic malignancy with a dismal prognosis, unless it is detected and treated promptly. An... (Review)
Review
BACKGROUND
Primary hepatic Burkitt lymphoma (PHBL) in children is an extremely rare hepatic malignancy with a dismal prognosis, unless it is detected and treated promptly. An 11-year-old child with abdominal pain was admitted to our hospital. No notable abnormalities were found during his physical examination or laboratory workup, but the abdominal computed tomography and magnetic resonance imaging both indicated a malignant hepatic mass measuring 9.2 × 7.1 × 7.5 cm in size. His postoperative pathology revealed an unexpected primary hepatic Burkitt lymphoma following a laparoscopic liver lobectomy. He then received rituximab and intense multi-agent chemotherapy as treatment. Despite post-chemotherapy bone marrow suppression, the patient eventually made a full recovery and had a good overall state.
CONCLUSION
In this study, we describe a rare case of pediatric primary hepatic Burkitt lymphoma and review the literature on clinical features, diagnosis, and treatment for primary hepatic Burkitt lymphoma in children. We stress that this diagnosis should be taken into account in the absence of other single hepatic lesions or primary tumors of hematological disorders, particularly when there is a normal AFP level.
Topics: Male; Humans; Child; Burkitt Lymphoma; Prognosis; Abdominal Pain; Rituximab; Abdomen
PubMed: 37482619
DOI: 10.1186/s12957-023-03052-3 -
Zhongguo Dang Dai Er Ke Za Zhi =... May 2022To study the clinical features and chemotherapy response of Burkitt's lymphoma (BL) in children and the influence of rituximab on the prognosis of children with BL.
OBJECTIVES
To study the clinical features and chemotherapy response of Burkitt's lymphoma (BL) in children and the influence of rituximab on the prognosis of children with BL.
METHODS
A retrospective analysis was performed for the medical data of 62 children with BL, including clinical features, therapeutic efficacy, and prognostic factors. The Cox regression model was used to identify the factors associated with poor prognosis in children with BL. According to whether rituximab was used, the children with advanced (stage III/IV) BL were divided into two groups: chemotherapy plus rituximab and chemotherapy alone. The prognosis was compared between the two groups.
RESULTS
For these 62 children, the median age of onset was 5 years (range 1-14 years), and there were 58 boys (94%) and 4 girls (6%). The primary site was abdominal cavity in 41 children (66%), and head and neck in 16 children (26%). There were 1 child with stage I BL (2%), 8 with stage II BL (13%), 33 with stage III BL (53%), and 20 with stage IV BL (32%). The median follow-up time was 29 months, with progression/recurrence observed in 15 children (24%), and the 3-year overall survival (OS) rate and event-free survival (EFS) rate were 82.8%±5.2% and 77.3%±5.8%, respectively. For the children with stage III/IV BL, there was a significant difference in the 3-year the OS rate between the chemotherapy plus rituximab group (16 children) and the chemotherapy alone group (30 children) (93.3%±6.4% vs 65.6%±9.9%, =0.042), while there was no significant difference in the 3-year EFS rate between the two groups (86.2%±9.1% vs 61.8%±10.1%, >0.05). The Cox regression analysis showed that central nervous system involvement, lactate dehydrogenase >1 000 U/L, and early incomplete remission were the factors associated with poor prognosis (<0.05).
CONCLUSIONS
Chemotherapy combined with rituximab can improve the prognosis of children with stage III/IV BL. Central nervous system involvement, elevated lactate dehydrogenase level, and early incomplete remission may indicate a poor prognosis in children with BL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Female; Humans; Infant; Lactate Dehydrogenases; Male; Prognosis; Retrospective Studies; Rituximab
PubMed: 35644197
DOI: 10.7499/j.issn.1008-8830.2111064 -
Current Opinion in Virology Oct 2016Burkitt lymphoma (BL) is >90% EBV-associated when this pediatric cancer is diagnosed in regions heavily burden by endemic Plasmodium falciparum malaria and thus has been... (Review)
Review
Burkitt lymphoma (BL) is >90% EBV-associated when this pediatric cancer is diagnosed in regions heavily burden by endemic Plasmodium falciparum malaria and thus has been geographically classified as endemic BL. The incidence of endemic BL is 10-fold higher compared to BL diagnosed in non-malarious regions of the world. The other forms of BL have been classified as sporadic BL which contain EBV in ∼30% of cases and immunodeficiency BL which occurs in HIV-infected adults with ∼40% of tumors containing EBV. Within malaria endemic regions, epidemiologic studies replicating Denis Burkitt's seminal observation continue to show differences in endemic BL incidence linked to intensity of malaria transmission. However, the mechanisms by which malaria contributes to B cell tumorigenesis have not been resolved to the point of designing cancer prevention strategies. The focus of this review is to summarize our current knowledge regarding the influence of prolonged, chronic malaria exposure on defects in immunosurveillance that would otherwise control persistent EBV infections. And thus, set the stage for ensuing mechanisms by which malaria could instigate B cell activation and aberrant activation-induced cytidine deaminase expression initiating somatic hypermutation and thereby increasing the likelihood of an Ig/Myc translocation, the hallmark of all BL tumors. Malaria appears to play multiple, sequential and simultaneous roles in endemic BL etiology; the complexity of these interactions are being revealed by applying computational methods to human immunology. Remaining questions yet to be addressed and prevention strategies will also be discussed.
Topics: Burkitt Lymphoma; Epstein-Barr Virus Infections; Humans; Incidence; Malaria, Falciparum; Plasmodium falciparum
PubMed: 27689909
DOI: 10.1016/j.coviro.2016.09.006